Moderna (MRNA) stock is spiraling Wednesday, down more than 8% at last check. Today's slide follows Tuesday's nearly 12% rally that was sparked by Monday's report from the Centers for Disease Control and Prevention (CDC) on the first death in the U.S. connected to the H5N1 bird flu.
The CDC said "the risk to the general public remains low" and that "no person-to-person transmission spread has been identified," but the news has caused volatility in Moderna's stock because it is developing a bird flu vaccine.
In July 2024, Moderna received $176 million from the U.S. Department of Health and Human Services to accelerate the development of its pandemic influenza vaccine, mRNA-1018.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population," the company said in a statement. Moderna's mRNA pipeline tracker currently shows that vaccine is in Phase 3 studies.
As of January 6, the CDC noted that there have been 66 confirmed cases of the H5N1 bird flu in the United States since 2024, with only one other case occurring between 2022 and 2024.
Is Moderna stock a buy, sell or hold?
Moderna hit its all-time high back in 2021 when the healthcare stock was capitalizing on surging demand for its COVID-19 vaccine. Since its price peak near $484 in August of that year, shares have tumbled almost 90%. And Wall Street remains cautious on the drugmaker.
According to S&P Global Market Intelligence, the average analyst target price on the large-cap stock is $73.64, representing implied upside of about 70% to current levels. Despite the implied upside, the consensus recommendation is Hold.
Financial services firm Argus Research is one of those firms with a Hold rating on MRNA stock.
"We think that MRNA shares are appropriately valued at recent prices below $45," wrote Argus Research analyst Jasper Hellweg in a December 17 note. "We would consider an upgrade when the company is able to return to a period of earnings growth and when it has more of its product candidates approved and sold on the market."
Related Content
-
Are You a Retirement Millionaire Too Scared To Spend?If you are too scared to spend money in retirement, you may be saddled with regret. Here are three ways to safely enjoy your sizable retirement nest egg.
-
U.S. Treasury to Eliminate Paper Checks: What It Means for Tax Refunds, Social SecurityTreasury President Trump signed an executive order forcing the federal government to phase out paper check disbursements by the fall.
-
Seven Questions to Ask When Evaluating Personal Loan OptionsTaking out a personal loan too hastily could lock you into unfavorable terms with an untrustworthy lender. Ask these questions before signing anything.
-
How Much Does Being Rich Matter in Retirement?After a certain point, having more money in retirement won't make you any happier, new research shows. Instead, physical health, a sense of purpose, and a minimal amount of non-mortgage debt are more relevant.
-
The Three Biggest Fears Keeping Retirees Up at NightHere are the steps you can take to put those fears to rest and retire with confidence so you can relax and enjoy the life you've planned.
-
What Can a Donor-Advised Fund Do for You? (A Lot)DAFs and private foundations go about helping charities (and those who donate) in different ways. Each comes with its own benefits and restrictions to navigate.
-
Estate Planning When You Have International AssetsEstate planning gets tricky when you have assets and/or beneficiaries outside the U.S. To avoid costly inheritance mistakes, it pays to understand the basics.
-
Microsoft Stock: Innovation Spurs Its 100,000% ReturnMicrosoft's ability to recognize the "next big thing" has allowed sales – and its share price – to grow exponentially over the years.
-
Three Essential Estate Planning Steps to Protect Your Nest EggAfter dedicating years to building your wealth and securing your future, make sure your assets are protected and your loved ones are provided for in the future.
-
Is Chasing the American Dream Ruining Your Financial Life?Too many people focus on visible affluence as a marker of success. Here's how to avoid succumbing to the pressure and driving yourself into debt.
